About Microtubule-associated protein RP/EB family member 1
Microtubule-associated protein RP/EB family member 1 (MAPRE1) is a protein
from Homo sapiens identified by UniProt accession
Q15691, 268 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | Microtubule-associated protein RP/EB family member 1 |
|---|
| UniProt accession | Q15691 |
|---|
| Gene | MAPRE1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 268 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (81)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- cup-to-disc ratio measurement · score 0.29
- DNA methylation · score 0.29
- mean platelet volume · score 0.28
- FEV/FVC ratio · score 0.26
- body height · score 0.23
- chronic lymphocytic leukemia · score 0.22
- hair colour measurement · score 0.20
- polycystic ovary syndrome · score 0.19
- head and neck squamous cell carcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15691-F1 | alphafold | PREDICTED | 80.38 | — |
Amino-acid sequence (268 residues)
MAVNVYSTSV TSDNLSRHDM LAWINESLQL NLTKIEQLCS GAAYCQFMDM LFPGSIALKK VKFQAKLEHE YIQNFKILQA GFKRMGVDKI IPVDKLVKGK FQDNFEFVQW FKKFFDANYD GKDYDPVAAR QGQETAVAPS LVAPALNKPK KPLTSSSAAP QRPISTQRTA AAPKAGPGVV RKNPGVGNGD DEAAELMQQV NVLKLTVEDL EKERDFYFGK LRNIELICQE NEGENDPVLQ RIVDILYATD EGFVIPDEGG PQEEQEEY
Explore Microtubule-associated protein RP/EB family member 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets